{"id":"W2614321241","doi":"10.1182/blood.v128.22.5010.5010","title":"Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Dabigatran; Idarucizumab; Direct thrombin inhibitor; Clinical trial; Intensive care medicine; Antithrombins; Adverse effect; Surgery; Internal medicine; Warfarin; Heparin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03585383,0.002380198,0.002371934,0.0007580658,0.001598406,0.001925722,0.002432589,0.003473286,0.01032168],"category_scores_gemma":[0.01849022,0.001352105,0.001656867,0.0007496026,0.002788201,0.001674254,0.001097035,0.004502541,0.002771557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001693274,"about_ca_system_score_gemma":0.009279645,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005278315,"about_ca_topic_score_gemma":0.001308011,"domain_scores_codex":[0.9791756,0.01608302,0.001044531,0.001359617,0.001534401,0.0008027932],"domain_scores_gemma":[0.989006,0.003524914,0.001872288,0.0009040336,0.001386774,0.003306007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.755098,0.04364572,0.04188094,0.006071969,0.002681087,0.001249574,0.001014714,0.004064003,0.01173654,0.01361004,0.01687435,0.102073],"study_design_scores_gemma":[0.5916241,0.3010097,0.02276418,0.001943266,0.002146096,0.0009006966,0.000328051,0.004842405,0.004044333,0.007157371,0.0630822,0.000157558],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.1374449,0.006214483,0.01818442,0.008052411,0.002439684,0.8070406,0.003632697,0.0001793389,0.0168116],"genre_scores_gemma":[0.3161453,0.002587306,0.03952792,0.009624339,0.001469962,0.6255043,0.00168548,0.00003367019,0.003421801],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.03585383,"threshold_uncertainty_score":0.1896155,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03190393013967593,"score_gpt":0.2925293139430571,"score_spread":0.2606253838033812,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}